ArticleTherapeutic advances in infectious disease
Missed opportunities to identify cryptococcosis in COVID-19 patients: a case report and literature review.
Article in Therapeutic advances in infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Post-COVID-19 Fungal Infection in the Aged Population.Vaccines · 2023Review
- Characteristics and Outcomes of Cryptococcosis among Patients with and without COVID-19.Journal of fungi (Basel, Switzerland) · 2022Article
- COVID-19 Associated with Cryptococcosis: A New Challenge during the Pandemic.Journal of fungi (Basel, Switzerland) · 2022Review
- Calcimycin InhibitsACS infectious diseases · 2022Article
- Cryptococcosis among hospitalised patients with COVID-19: A multicentre research network study.Mycoses · 2022Article
- Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients.Journal of fungi (Basel, Switzerland) · 2022Review
- Invasive cryptococcal disease in COVID-19: systematic review of the literature and analysis.Le infezioni in medicina · 2022Review
- Overview of COVID-19-Associated Invasive Fungal Infection.Current fungal infection reports · 2022Review
- Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: a case report and literature review.Therapeutic advances in infectious diseaseArticle
- Epidemiological trends and clinical outcomes of cryptococcosis in a medically insured population in the United States: a claims-based analysis from 2017 to 2019.Therapeutic advances in infectious diseaseArticle
- COVID-19 associated with cryptococcosis: a scoping review.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 may activate both innate and adaptive immune responses ultimately leading to a dysregulated immune response prompting the use of immunomodulatory therapy. Although viral pneumonia increases the risk of invasive fungal infections, it remains unclear whether SARS-CoV-2 infection, immunomodulatory therapy, or a combination of both are responsible for the increased recognition of opportunistic infections in COVID-19 patients. Cases of cryptococcosis have previously been reported following treatment with corticosteroids, interleukin (IL)-6 inhibitors, and Janus kinase (JAK) inhibitors, for patients with autoimmune diseases, but their effect on the immunologic response in patients with COVID-19 remains unknown. Herein, we present the case of a patient with COVID-19 who received high-dose corticosteroids and was later found to have cryptococcosis despite no traditional risk factors. As our case and previous cases of cryptococcosis in patients with COVID-19 demonstrate, clinicians must be suspicious of cryptococcosis in COVID-19 patients who clinically deteriorate following treatment with immunomodulatory therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.